Printer Friendly

ImpactRx Releases Key Data on U.S. Pharmaceutical Promotion Activity; - Keynote Presentation From Joint Conference with Prudential Financial Now Accessible on -.

MOUNT LAUREL, N.J., July 7 /PRNewswire/ -- ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation's highest prescribing physicians, today announced that the keynote presentation from the Prudential Financial/ImpactRx joint conference on "Drug Launches and The Impact of Pharmaceutical Promotion on Physician Treatment Decisions," that was held on June 20, 2003 in New York City, has been uploaded to the ImpactRx website and is available at ImpactRx was the sole source of data presented at the conference, which was hosted by Timothy M. Anderson, M.D., Senior Vice President and Senior Analyst, Pharmaceuticals, of Prudential Financial.

"It is unique to have a conference that drills down into the analytics in this way," said Dr. Anderson. "In the one-year that Prudential Financial has been utilizing ImpactRx data to augment other sources of data, we have routinely gotten a leg up on our competitors in terms of discerning specific indicating factors beneath the surface of such major events as new drug launches. This conference gave us the opportunity to share this newfound source of intelligence with our clients and articulate how the factors tracked in this data are critical to a product's ultimate commercial success."

The keynote presentation, delivered by ImpactRx Co-Founder Terry Overton, Ph.D., provided an overview of the data ImpactRx captures on the efficiency of the industry's sales forces and a narrative on the nature of personal pharmaceutical promotion in the United States today. Also presenting from ImpactRx were Gerald J. Gallivan, Co-Founder, Chairman and Chief Executive Officer, Robert Caprara, Vice President, Advanced Analytics and Martin Glogowski, Vice President, Market Research. The presentations delivered by these speakers have also been posted to the ImpactRx website ( in addition to the keynote presentation.

"We are very encouraged by the high level of interest our data received from the buy-side analysts attending the Prudential conference," said Mr. Gallivan. "To have ImpactRx data utilized -- and recognized in a public forum -- by one of the most respected securities firms in the world is an invaluable endorsement of our capabilities."

About ImpactRx

ImpactRx comprehensively collects data on promotion and physician treatment decisions for every pharmaceutical product currently marketed in the United States from its exclusive network of high prescribing physicians. Founded in October 2000, ImpactRx's physician network is the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and measuring their effect on prescribing behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners ( and Oxford Bioscience Partners (

CONTACT: Patrick Angelastro, Vice President, Marketing & Client Services of ImpactRx, Inc., +1-856-273-0221, ext. 102,; or Pete Holmberg (Media), +1-917-322-2164,, or Melody A. Carey (Investors), +1-917-322-2571,, both of Rx Communications Group, LLC, for ImpactRx, Inc.

Web site:
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 2003
Previous Article:TradeWeb Posts Record Volumes in Five Fixed-Income Markets; Low Yields and High Volatility Fuel $4.8 Trillion in Online Bond Markets Volume.
Next Article:Atkins Launches New Breakfast Bars to Wake Up Carb-Conscious Americans; Mornings can be hectic, and sometimes breakfast gets lost in the shuffle;...

Related Articles
ImpactRx Builds On Previous Financing With $3 Million From Merck Capital Ventures; - Series C Round Now Stands at $13 Million -.
ImpactRx Expands Sales And Service Capability; - David N. Stievater Joins as Vice President, Sales.
Mark B. McClellan, FDA Commissioner, Addresses Clinical Trial Inefficiencies at IIR's Phases: Maximizing Clinical Efficiency Conference, October...
ImpactRx Expands to Provide Decision Support on Dermatology Market; Company Announces Addition of Dermatology Physician Specialty to Nationwide...
Nancy S. Lurker Named Chief Executive Officer and President Of ImpactRx; -- Nation's First Pharmaceutical Promotion Response Organization Selects BMS...
Fixing the Broken Pharmaceutical Marketing Machine Focus of Upcoming Pharmaceutical Marketing Global Summit Meeting February 24-26, 2004 in...
Patient Compliance Low-Hanging Fruit for Increased Pharmaceutical Profitability, Growth, and Sales.
AstraZeneca Awards ImpactRx Sales Force Measurement Project; ~Company to Track Sales Force Effectiveness for Leading Brands~.
ImpactRx Announces the Launch of ONCLink(TM) and the Formation of an Oncology Business Unit.
ImpactRx Tracks Decline in Zetia and Vytorin Prescribing.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters